InnovaRx Innova Health Strategies
Pricing Sign in

E16.4

Increased secretion of gastrin

Billable FY2026 2025-10-01 → 2026-09-30
Exclusions 1 never code together
E00-E89chapter
Excludes1
  • transitory endocrine and metabolic disorders specific to newborn (P70-P74)P70-P74

Excludes1 — never code together. The excluded condition and this one are mutually exclusive.

Instructional notes 4
E16.4code
Inclusion terms
  • Hypergastrinemia
  • Hyperplasia of pancreatic endocrine cells with gastrin excess
  • Zollinger-Ellison syndrome
E00-E89chapter
Notes
  • All neoplasms, whether functionally active or not, are classified in Chapter 2. Appropriate codes in this chapter (i.e. E05.8, E07.0, E16-E31, E34.-) may be used as additional codes to indicate either functional activity by neoplasms and ectopic endocrine tissue or hyperfunction and hypofunction of endocrine glands associated with neoplasms and other conditions classified elsewhere.E05.8E07.0E16-E31E34.-
Index entries leading here 7
  • Abnormal, abnormality, abnormalities — see also Anomaly
  • Hyperplasia, hyperplastic
  • Ellison-Zollinger syndrome E16.4
  • Hypersecretion
  • Increase, increased
    • secretion
  • Hypergastrinemia E16.4
  • Zollinger-Ellison syndrome E16.4
Alongside this code 7 same parent — E16
E16.0 Drug-induced hypoglycemia without coma E16.1 Other hypoglycemia E16.2 Hypoglycemia, unspecified E16.3 Increased secretion of glucagon E16.8 Other specified disorders of pancreatic internal secretion E16.9 Disorder of pancreatic internal secretion, unspecified E16.A Hypoglycemia level category
Additional references
AHA Coding Clinic® Licence required

Official coding advice for this code. Published by the American Hospital Association. Not included in this installation.

Risk adjustment

RX08HCC66

Presence is a property of the code. Untick a model to hide it everywhere.

This code

Billable
yes
Code set
FY2026
Parent
E16
Block
E15-E16
Siblings
7

Present FY2024–FY2027.